Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasminogen activators: a comparison.

Dev B Baruah1, Rajendra N Dash, M R Chaudhari

  • 1Department of Quality Assurance Techniques, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038, India.

Vascular Pharmacology
|November 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal hyperlipidemia with pancreatitis: Novel gene mutation of lipoprotein lipase.

Journal of postgraduate medicine·2018
Same author

Kinetics study of metaxalone degradation under hydrolytic, oxidative and thermal stress conditions using stability-indicating HPLC method.

Journal of pharmaceutical analysis·2018
Same author

Formulation and Solid State Characterization of Nicotinamide-based Co-crystals of Fenofibrate.

Indian journal of pharmaceutical sciences·2015
Same author

Hand hygiene behavior among urban slum children and their care takers in Odisha, India.

Journal of preventive medicine and hygiene·2015
Same author

Comparative analysis of routine laboratory diagnostic tests for rabies.

Indian journal of virology : an official organ of Indian Virological Society·2013
Same author

A stability-indicating high performance liquid chromatographic method for the determination of diacerein in capsules.

Indian journal of pharmaceutical sciences·2010
Same journal

Interplay between Na<sup>+</sup>/K<sup>+</sup>-ATPase-dependent Src-mediated Ca<sup>2+</sup> sensitization and BK<sub>Ca</sub> channel negative feedback regulates rat mesenteric artery contraction.

Vascular pharmacology·2026
Same journal

Generation and validation of a Myh11Dre-Spp1Cre intersectional mouse model for lineage tracing of disease-associated smooth muscle cell states.

Vascular pharmacology·2026
Same journal

Prediction of peri-procedural cerebrovascular accidents in patients with severe peripheral artery disease undergoing transcatheter aortic valve replacement.

Vascular pharmacology·2026
Same journal

Vascularized tumor organoids as models for interpreting therapeutic response.

Vascular pharmacology·2026
Same journal

Spermidine ameliorates BK channel dysfunction in diabetic coronary smooth muscle cells via PKM2/STAT3/FBXO32 axis.

Vascular pharmacology·2026
Same journal

Reassessing the role of PPARgamma in vascular effects of cannabinoids: A critical appraisal.

Vascular pharmacology·2026
See all related articles

Thrombolytic drugs are vital for treating various thrombotic diseases. Newer plasminogen activators offer improved fibrin specificity and easier administration for effective thrombus resolution.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombolytic drugs are essential for managing acute thrombotic events.
  • The fibrinolytic system's role in clot breakdown is well-established.
  • Development of fibrinolytic agents has evolved significantly.

Purpose of the Study:

  • To review the role of thrombolytic drugs in various thrombotic conditions.
  • To highlight the advancements in fibrinolytic agent development.
  • To discuss the properties of newer plasminogen activators.

Main Methods:

  • Literature review of thrombolytic therapy and fibrinolytic agents.
  • Analysis of pharmacokinetic and pharmacodynamic properties of newer drugs.
  • Comparison of traditional and novel thrombolytic approaches.

Related Experiment Videos

Main Results:

  • Thrombolytic drugs are critical for acute myocardial infarction, pulmonary embolism, and deep vein thrombosis.
  • Newer plasminogen activators exhibit enhanced fibrin specificity.
  • These advanced agents possess prolonged half-lives and allow for single bolus administration.

Conclusions:

  • Novel fibrin-specific plasminogen activators represent a significant advancement in treating thrombotic diseases.
  • Improved pharmacokinetic profiles enhance therapeutic efficacy and patient convenience.
  • Continued research into thrombolytic agents promises better outcomes for thrombotic conditions.